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Introduction {#sec1}
============

Ebola virus (EBOV) is the prototypic virus of the genus *Ebolavirus*, a group of viruses associated with severe and frequently fatal disease in humans and nonhuman primates (NHP). The genus is a member of the family Filoviridae (order Mononegavirales), which includes the genera *Marburgvirus*, *Cuevavirus*, *Striavirus*, and *Thamnovirus* ([@bib34]; [@bib51]; [@bib80]). EBOV has caused the two largest filovirus outbreaks in recorded history: the West African epidemic of 2013--2016 ([@bib3]) and the recent outbreak in the Democratic Republic of the Congo (DRC), which began in August 2018 and was contained only with substantial effort ([@bib52]; [@bib77]). The Egyptian fruit bat (*Rousettus aegyptiacus*), a megabat native to much of sub-Saharan Africa, has been definitively identified as a reservoir for viruses of the genus *Marburgvirus* ([@bib69]), and strong evidence indicates that bats serve as the primary reservoir for EBOV as well ([@bib20]; [@bib39]; [@bib43]; [@bib54]; [@bib67]). Of particular note, EBOV RNA has been detected in bats of four species, *Hypsignathus monstrosus*, *Epomops franqueti*, *Myonycteris torquata*, and *Miniopterus inflatus* ([@bib39]; [@bib13]).

Like most RNA viruses, filoviruses encode a non-proofreading RNA-dependent RNA polymerase (RdRP). Consequently, genomic replication is far more error prone than in other organisms, resulting in higher mutation rates ([@bib27]). RNA virus genomes therefore face strong selective pressure to exhibit a significant degree of mutational robustness ([@bib37]). Another consequence is their remarkable ability to adapt to new replicative environments ([@bib4]). RNA virus replication produces complex population structures in which the replication of a single "master genome" (the consensus sequence) gives rise to a large, complex, and interconnected "mutant swarm" of variant genomes of varying degrees of fitness relative to the master genome. The impact of intra-host genetic diversity on virulence and fitness within the host is well documented for numerous RNA viruses, including hepatitis C virus ([@bib15]), several enteroviruses ([@bib47]; [@bib57]; [@bib73]), chikungunya virus ([@bib8]), and West Nile virus ([@bib21], [@bib22]), in which reduced diversity of virus populations results in lower fitness and an attenuated infection phenotype. Mutation rates of RNA viruses are difficult to determine, but are estimated at the order of 10^−6^--10^−4^ substitutions/nucleotide/cycle of replication ([@bib27]; [@bib56]). Although the mutation rate of EBOV is not firmly established, the evolutionary rate of the virus in humans (the rate at which genetic variants arise and proliferate throughout a virus population) is estimated to be ∼4.7 × 10^−4^ substitutions/site/year when averaged across all outbreaks from 1976 to 2018 ([@bib46]). However, this figure is not directly comparable with mutation rate, as multiple factors, including population size and demographic trends (e.g., population growth rate, bottlenecks), affect observed evolutionary rates. Furthermore, these estimates of EBOV evolutionary rates are derived from consensus sequences obtained from human cases and do not reflect evolution in the natural reservoir of the virus. Although the effects of host-specific conditions on the observed mutation rate of EBOV are unknown and may or may not differ between reservoir and non-reservoir hosts, the factors that dictate evolutionary rate during circulation (i.e., positive/negative selection, genetic drift) likely vary ([@bib28]). Experimental data demonstrate that the animal passage history of EBOV influences its infectivity and virulence during subsequent infection of a new host species, and a similar effect is presumed to occur in natural settings ([@bib17]).

The 2013--2016 West African EBOV epidemic generated an unprecedented abundance of sequencing data. Several fixed putative adaptive mutations were identified. Furthermore, at least two and possibly three of these were under positive selection ([@bib9]; [@bib10]; [@bib71]). Despite exhibiting increased fitness in cell culture, no obvious difference in pathogenicity from the parental virus was found in mouse and rhesus macaque models of EBOV infection ([@bib45]). However, mice do not recapitulate human or NHP disease, and the size of the rhesus macaque groups used was insufficient to detect a possible shift in pathogenicity. Furthermore, no significant attempt was made to determine any effect of the mutants on transmission, a significant contributor to the fitness of a virus during an outbreak. In the present study, we sought to characterize EBOV adaptation to cells of bat and human origin. In order to assess changes in mutation rates and the structure of EBOV populations during serial passage through either human (293T) or bat (EpoNi/22.1, *Epomops buettikoferi*) renal cell lines, we used circular sequencing (CirSeq) ([@bib2]). CirSeq is an Illumina platform-based ultra-deep-sequencing approach that uses specialized library preparation and computational protocols to eliminate the vast majority of sequencing errors, reducing the error rate of sequencing to as low as 10^−12^ per base. This permits variant calls at a far lower threshold. We identified differences in individual nucleotide mutation rates, as well as observed a number of host-specific mutations that appeared to have undergone positive selection. In addition, a particularly prominent cluster of mutations in the region spanning the glycan cap (GC) and mucin-like domain (MLD) of the glycoprotein (GP) of EBOV passaged in EpoNi/22.1 cells was identified. Finally, we selected several mutants from each cell line for further investigation using both infectious EBOV prepared via reverse genetics and the EBOV minigenome (MG) system. Along with characterization of replication kinetics in each cell line, co-infection experiments were performed to assess the fitness of the selected mutant viruses relative to wild-type EBOV. Our results offer insight into the effects of host factors on the evolution of EBOV and highlight the capacity of the virus to rapidly develop potentially adaptive mutations in diverse hosts. Given the ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, and the likely origin of this virus in bats, expanding our understanding of the evolution of viruses in their bat hosts is of particular relevance at this time.

Results {#sec2}
=======

Experimental Evolution through Serial Passaging of EBOV in Human and Bat Cells {#sec2.1}
------------------------------------------------------------------------------

The cell line EpoNi/22.1, derived from renal epithelia of an adult *Epomops buettikoferi*, was selected as the bat cell line used for passaging. This species is a close relative of *Epomops franqueti* ([@bib26]). 293T cells, derived from human embryonic kidney, were used for comparison. These cell lines were selected because of their similar tissue origin and the fact that they replicate the virus to similar titers. The latter is an important consideration for population genetics, as vastly divergent population sizes complicate analysis.

EBOV was rescued from the full-length clone plasmid in 293T cells. Passage 2 (p2) virus was blind-passaged three times in either EpoNi/22.1 or 293T cell lines for initial "adaptation." This step reduces the risk of interference from any extremely high-fitness mutations associated with early passage in each cell line that may either obscure or artificially inflate the fitness of lower frequency mutations. Next, viruses were put through two rounds of terminal dilution. Three clonal isolates were selected from each cell line. Resulting titers were low, and two rounds of amplification in their respective cell lines were required. For experimental passages, monolayers of 293T or EpoNi/22.1 were inoculated at multiplicity of infection (MOI) 0.1 plaque-forming units (PFU)/cell. The first passage in 293T was performed at MOI 0.01 PFU/cell for all replicates, as the titer was low following the amplification passages. This process was repeated for a total of seven experimental passages. Supernatants from each passage were collected, and virus was purified via sucrose gradient for subsequent RNA extraction and sequencing. [Figure 1](#fig1){ref-type="fig"} presents an overview of the experiment. In 293T, titers for clones A and C remained relatively stable throughout the passage series; however, starting in passage 6, a precipitous decline in titer was observed for clone B ([Figure S1](#mmc1){ref-type="supplementary-material"}). No substantial difference was observed in the three clones passaged in EpoNi/22.1.Figure 1Schematic of Passaging Experimental Design

EBOV Takes Distinct Evolutionary Paths in Human-Derived and Bat-Derived Cell Lines {#sec2.2}
----------------------------------------------------------------------------------

Viral genomic RNA isolated after each passage was used to prepare libraries for CirSeq ([@bib1]; [@bib2]). First, the data were used to calculate individual mutation frequencies for each possible nucleotide variant (A to G, C to A, U to C, etc.) ([Figure 2](#fig2){ref-type="fig"} A). Averaged over all clones and passages, we found that overall mutation frequencies were similar between the EpoNi/22.1 and 293T-derived viruses, with the exception of G-to-A transitions. We found there was a significant increase in the frequency of G-to-A mutations (with respect to the EBOV genomic strand) in the EpoNi/22.1-derived viral populations relative to 293T ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Population-Level Characterization of Passaged EBOV Populations(A) Mutation frequencies for each type of nucleotide substitution. Each boxplot represents 21 data points (three clones over seven passages). ^∗∗∗^Corrected p value \< 10^−4^. Error bars denote ±SD.(B) Identical to (A), but mutation frequencies were calculated on a per ORF basis rather than across the entire genome. G-to-A mutations are significantly elevated in EpoNi/22.1 cells across all ORFs (all corrected p values \< 10^−3^). "Non-coding" represents all non-coding regions as a single entity. Error bars denote ±SD.

To determine if mutation rates within individual viral genes differed between cell lines, we recalculated individual mutation frequencies, treating each open reading frame (ORF) as an independent region. Frequencies were consistent, indicating no gross differences in the spontaneous RdRP mutation rate due to genomic position ([Figure 2](#fig2){ref-type="fig"}B). This also held true for the elevated frequency of G-to-A substitutions observed in EpoNi/22.1-derived viral genomes, with all examined regions exhibiting a similar pattern relative to 293T-derived virus ([Figure 2](#fig2){ref-type="fig"}B).

Clear differences in variant frequencies at the final passage highlight the distinct evolutionary paths of the 293T-passaged and EpoNi/22.1-passaged populations ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). Comparing Shannon entropy over time, we found a high degree of homogeneity in passage 1, with increasing heterogeneity over the course of passaging ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Overall, the average genomic Shannon entropy estimated in the EpoNi/22.1-passaged replicates was moderately higher than in their 293T-passaged counterparts ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

EBOV Populations Passaged in Bat-Derived Cells Exhibit a "Spike" of High-Frequency Mutations Consistent with ADAR Activity in the GC/MLD Region of the GP Protein {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

An intriguing pattern of mutations arose during passaging of EBOV in EpoNi/22.1 cells. Two of the three EpoNi/22.1-passaged viral populations acquired localized peaks of high-frequency variants over the course of passaging ([Figure 3](#fig3){ref-type="fig"} A). These mutations arose primarily after passage 4 and consisted almost entirely of adenosine (A)-to-guanine (G) substitutions (genomic sense). These peaks of mutations were localized within the region spanning the GC and MLD regions of GP ([Figure 3](#fig3){ref-type="fig"}B). An increased frequency of A-to-G substitutions in these regions was also detected in the other passage series (including the 293T-derived populations), albeit at a lower frequency.Figure 3EpoNi-Passaged Virus Accumulates High-Frequency A-to-G Mutations(A) Variant frequencies plotted against nucleotide position, color-coded by type of amino acid change at passages 1 and 7 of the EpoNi/22.1 "C" population.(B) Detailed view of the GP coding region, showing only A-to-G (genomic sense) mutations. The majority of mutations in the high-frequency "spike" are A to G and localize primarily within the glycan cap (GC; blue) and mucin-like domain (MLD; purple) of GP (yellow).(C) Average number of A-to-G (solid lines) and U-to-C (dashed lines) mismatches per read in EpoNi/22.1-derived (left panel) and 293T-derived (right panel) virus genomes. Only reads longer than 80 bp were examined.(D) Same as (C), but filtered to reads containing at least one mutation of the indicated type.

As a result of the relatively small size of the region in which they were located, we were able to determine if multiple mutations appeared on a single genome. In two of the three replicates passaged in EpoNi/22.1, the average number of A-to-G substitutions (genomic strand) per read (i.e., genome) increased dramatically over the course of passaging ([Figure 3](#fig3){ref-type="fig"}C, solid lines), while U-to-C substitutions did not ([Figure 3](#fig3){ref-type="fig"}C, dashed lines). EBOV therefore accumulates these A-to-G mutations on the same genomes without apparent detriment. Interestingly, the passage EpoNi/22.1 A exhibited a higher average number of mutations per read than the two other replicates ([Figure 3](#fig3){ref-type="fig"}D). Such a high level of mutational robustness is supported by previous studies in other viruses ([@bib37]).

A compelling explanation for this phenomenon is editing activity associated with the ADAR family of RNA editing enzymes. ([@bib75]). ADARs edit double-stranded RNA (dsRNA) by creating adenosine-to-inosine mutations, ultimately resulting in A-to-G substitutions. ADARs have been implicated in editing the genomes of a number of viruses ([@bib7]; [@bib18]; [@bib32]; [@bib58]; [@bib62]), including EBOV ([@bib12]; [@bib55]; [@bib65]; [@bib68]; [@bib76]). We investigated whether any ADAR motifs were enriched in the highest frequency variants in this region. Examination of the 10 nucleotides surrounding the most frequent A-to-G (genomic strand) variants revealed a motif matching that expected of ADAR editing (5′-\[U/A/C\]AG/U-3′) ([Figures 4](#fig4){ref-type="fig"}A and 4B) ([@bib14]). Lending further support to the hypothesis of ADAR editing in viral populations derived from EpoNi/22.1, we found that EpoNi/22.1 cells express approximately 12-fold more ADAR1 mRNA than 293T cells. EBOV infection did not significantly increase ADAR1 expression in either cell line ([Figure 4](#fig4){ref-type="fig"}C). However, it appears that this enhanced expression is either a feature of *Epomops* bats or their subfamily (Epomophorinae) ([Figures 4](#fig4){ref-type="fig"}C and 4D).Figure 4High-Frequency A-to-G Mutations in EpoNi/22.1 Are Likely the Result of ADAR Activity(A) Sequence logo (SeqLogo) of nucleotides surrounding the most frequent A-to-G (genomic sense) mutations. Each tier represents the SeqLogo of A-to-G mutations that were in the top 80% (by frequency, upper panel) or top 60% (middle panel) in all three populations from EpoNi/22.1-passaged virus at passage 7. "All" (lower panel) represents SeqLogo of surrounding nucleotides for all A's in the examined region.(B) pLogo plot of high-frequency A-to-G mutations in EpoNi/22.1 passages (genomic sense). The 0.5 quantile of the most frequent A-to-G substitutions (determined with the same methodology as in A) was compared with the entire region from nucleotides 6,723 to 7,540. Only the depletion of "G" in the +1 position relative to suspected ADAR target sites was identified as statistically significant (p \< 0.5).(C) qRT-PCR (absolute quantitation) for ADAR1 normalized to 18 s rRNA copy number. Comparison of ADAR1 values for EpoNi/22.1 with that for the human cell lines tested: ^∗∗∗∗^p \< 0.0001, one-way ANOVA with Tukey's post hoc test. Error bars denote ±SD.(D) Previous panel with EpoNi/22.1 removed to show variation among bat cell lines. Error bars denote ±SD.

In summary, we have found that during our passaging experiments in bat cells, a region encompassing parts of the GC and MLD of EBOV GP undergoes hypermutation in the form of a drastic increase in the rate of A-to-G mutations. These mutations are consistent with the described editing activity of ADAR, an isoform of which was found to be expressed in significantly greater quantities in the bat species or cell line used relative to human cells.

Human and Bat Cell Passage-Produced Viruses Have Distinct Population Structures {#sec2.4}
-------------------------------------------------------------------------------

In addition to the "spike" of mutations in GP found only in EpoNi/22.1-passaged viruses, we identified individual mutations that rose in frequency over the course of passaging. To identify these, we searched for variants that rose in frequency in at least two of the three EBOV clones passaged in cells derived from each host. Several variants in 293T-derived populations identified were in regions associated with transcriptional regulation. These included mutations in NP, VP30, and the gene-end/transcription termination signal of the VP40 gene ([Figure 5](#fig5){ref-type="fig"} ; [Figure S4](#mmc1){ref-type="supplementary-material"}). In NP, variants were found within the protein phosphatase 2 (PP2) interaction domain ([@bib41]), while those in VP30 were near the region of the protein responsible for interaction with NP ([Figure S5](#mmc1){ref-type="supplementary-material"}). Protein modeling revealed that mutations identified in VP30 were predicted to decrease the stability of the protein ([Figure S6](#mmc1){ref-type="supplementary-material"}A). The mutations identified in the VP40 gene-end/transcription termination signal (ATTAAGAAAAAA) ([@bib5]) are as follows, with mutated nucleotides underlined: [G]{.ul}TTAAGAAAAAA, ATTA[G]{.ul}GAAAAAA, A[C]{.ul}TAAGAAAAAA, and AT[C]{.ul}AAGAAAAAA. These mutations were not generally found to co-occur on the same reads (data not shown). Also identified in 293T passages was a variant cluster within the capping domain of the L ORF ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Other than the spike of mutations in GP, the only variant cluster identified by visual examination in EpoNi/22.1 was within the methyltransferase domain of the L ORF. [Figure S6](#mmc1){ref-type="supplementary-material"}B illustrates the predicted impacts of the mutations identified in both cell lines on the stability of L polymerase.Figure 5Frequency Trajectories of Variants with Differential Behavior between Host Cells(A) Mutations that accumulate faster in 293T-derived populations relative to EpoNi/22.1-derived virus over the course of passaging.(B) Mutations which accumulate faster in EpoNi/22.1 relative to 293T-derived virus genomes.

Notably, most of the identified mutations did not closely approach fixation in either 293T or EpoNi/22.1 and could be identified only using ultra-deep-sequencing technology, without resorting to a large number of passages. This demonstrates the utility of CirSeq in experimental evolution studies. Variant frequency trajectories for representative mutants that exhibited higher fitness in one cell line are shown in [Figure 5](#fig5){ref-type="fig"}. Overall, we found that passaging had host-specific effects on population structure. Therefore, we sought to determine the effects of these differences by characterizing the infection phenotypes of representative mutants.

Human and Bat Cell-Derived Mutants Displayed Cell-Specific Fitness Patterns {#sec2.5}
---------------------------------------------------------------------------

A total of six mutants, five of which (VP40 t5885c is excluded) are shown in [Figure 5](#fig5){ref-type="fig"}, were selected for characterization. Four mutants were identified in 293T-passaged virus, while two were from EpoNi/22.1-passaged virus. Mutants selected displayed a consistent upward trend in at least two clones during passaging and were generally the most fit within their variant cluster. Mutations in ORFs were tested through generation of recombinant viruses using the EBOV full-length clone, while the single untranslated region (UTR) mutant (t5885c) was tested in a VP40/GP bicistronic MG that was developed for this purpose. Replication kinetics assays were performed under multistep conditions in both 293T and EpoNi/22.1 cells. Given the apparent functional relatedness of the mutants, we attempted to construct a double mutant containing the NP and VP30 mutant genes identified in [Figure 5](#fig5){ref-type="fig"}. Multiple attempts to rescue this virus failed, suggesting that it is nonviable (data not shown).

Averaged across time points, all mutant viruses had a replicative advantage over the parental wild-type virus in 293T ([Figure 6](#fig6){ref-type="fig"} A). In EpoNi/22.1, only GP L256P (identified in EpoNi/22.1) had a meaningful advantage over wild-type ([Figure 6](#fig6){ref-type="fig"}A). We also identified cell-specific differences in the infection phenotype of both L polymerase mutants. L C1211R, identified in 293T, exhibited a marked deficiency in EpoNi/22.1 ([Figure 6](#fig6){ref-type="fig"}A). The virus also had a small plaque phenotype on Vero E6 ([Figure 6](#fig6){ref-type="fig"}B). In comparison, this mutation was neutral to mildly beneficial in 293T. In contrast, single-step kinetics assays performed in EpoNi/22.1 found that L S1994G (identified in EpoNi/22.1) had a significant advantage over wild-type under these conditions (data not shown). Additionally, L S1994G exhibited a large plaque phenotype on Vero E6 ([Figure 6](#fig6){ref-type="fig"}B). Finally, a dual luciferase MG assay was used to demonstrate the potential role of noncoding mutations. We found that the mutation identified in the VP40 gene-end/transcription termination signal, t5885c (t5888c on the cDNA clone used to generate the passaged virus, reflected in figures), impaired translation of the second (Renilla luciferase) ORF downstream of the disrupted gene-end signal ([Figure 6](#fig6){ref-type="fig"}C).Figure 6Phenotypic Effects of the Selected Mutations(A) Multi-step growth kinetics of EBOV wild-type (WT) and mutant viruses in 293T and EpoNi/22.1 cells. Monolayers of 293T or EpoNi/22.1 cells were infected at MOI 0.01 PFU/cell in triplicate. Supernatants collected, then titrated on Vero E6 cells as technical duplicates. 293T-derived and EpoNi/22.1-derived mutants are shown as solid lines and dashed lines, respectively. Limit of detection (2 log PFU/mL) indicated with a dashed line. Error bars denote ±SD.(B) Immunostain plaque phenotypes.(C) VP40 gene-end region mutant reduces translation of the second ORF in a bicistronic minigenome. Ratio of firefly luciferase (first ORF) to Renilla luciferase (second ORF) reflects the efficiency of translation of the second ORF. ^∗∗∗∗^p \< 0.0001 (unpaired t test with Welch's correction). Experiment performed with biological triplicates. No L and no minigenome controls were performed but are not shown. Firefly luciferase activity for these controls was significantly lower than in full plasmid transfections (p \< 0.05 by one-way ANOVA with Tukey's post hoc test).

To better understand the fitness relationships between the mutants and wild-type EBOV, competition assays were performed in both cell lines, as shown in [Figure 7](#fig7){ref-type="fig"} A. All mutants were observed to displace the wild-type virus under low-MOI "competition" conditions in both cell lines, with the exception of L C1211R in EpoNi/22.1 cells ([Figure 7](#fig7){ref-type="fig"}B), repeating the results of the kinetics assays. However, the kinetics of replacement were variable between viruses and cell lines. The fitness of the 293T-origin mutant L C1211R was very cell line dependent, in contrast to L S1994G, which was detected in EpoNi/22.1 ([Figure 7](#fig7){ref-type="fig"}B). Although the EpoNi/22.1-origin GP L256P was more fit than wild-type in both cell lines, its kinetics of displacement were more rapid in EpoNi/22.1 cells, consistent with our replication kinetics results ([Figure 7](#fig7){ref-type="fig"}B). The fitness of mutations in polymerase accessory proteins showed little cell line dependency. The only notable trend under high-MOI "complementation" conditions was the slow displacement of NP N566S with VP30 E205G ([Figure 7](#fig7){ref-type="fig"}B).Figure 7EBOV WT and Mutant Virus Competition and Complementation Assays(A) Schematic of experimental design.(B) Data shown are representative of three biological replicates for most competition/complementation assays. Two replicates were analyzed for the following: 293T EBOV WT/NP N566S, EBOV WT/L C1211R p4 competition assays, EpoNi/22.1 EBOV WT/NP N566S and EBOV GP L256P p3 competition assays, and EBOV WT/L C1211R p4 competition assays. One replicate was analyzed for the EpoNi/22.1 EBOV WT/VP30 E205G p4 competition assay. Additionally, because of the inability to generate an amplicon suitable for Sanger sequencing, EpoNi/22.1 EBOV WT/NP N566S and WT/GP L256P p4 competition assays were omitted from the analysis. Sequencing of RT-PCR amplicons was performed with technical duplicates, with the average of the two proportions being used. Error bars denote ± SD. Asterisks denote complementation assays, relative frequency of gene in parentheses displayed.

Discussion {#sec3}
==========

The evolution of EBOV in EpoNi/22.1 cells during passaging was remarkably different from that observed in 293T cells. Although divergent evolutionary patterns are not unexpected, the degree and nature of the differences were notable. Although the observed mutation rates were similar in both cell lines, the finding that the rate of G-to-A substitutions was significantly greater in EpoNi/22.1 is particularly important ([Figure 2](#fig2){ref-type="fig"}). A potential explanation for this finding is RNA editing of the positive sense complementary RNA (cRNA) by a host factor. C-to-U mutations in the cRNA, such as those catalyzed by the APOBEC family, would produce G-to-A mutations in the resulting genomic RNA ([@bib24]). Although intriguing, further investigation is required to identify the root cause of this difference and the role host factors may play. Notably, the antiviral effect of APOBEC3 in bats has recently been explored ([@bib25]).

Evidence for host RNA editing enzyme activity in EpoNi/22.1 cells was found in the GP gene. We observed a spike of high-frequency A-to-G mutations in a region spanning the GC and MLD of GP in EpoNi/22.1-passaged EBOV ([Figure 3](#fig3){ref-type="fig"}). These regions are known to be favored targets of the humoral immune response during infection ([@bib16]), and high-frequency mutations here would be expected in the presence of such strong selective pressure. However, there were no antibodies present during our passaging, and both coding and non-coding mutations were identified. Additionally, the truly massive number of mutations present, and the rate at which these mutations accumulated after passage 4 in EpoNi/22.1 cells, suggests the activity of a host RNA editing factor. Further investigation demonstrated that this pattern was likely the result of ADAR family RNA editing enzyme activity. ADAR editing of (-)ssRNA (single-stranded RNA) virus genomes is well documented and has been shown to have both proviral and antiviral effects ([@bib18]; [@bib62]; [@bib66]). Although 293T-passaged viruses had A-to-G mutations similar to those identified in EpoNi/22.1 cells, the frequency was far lower, suggesting that ADAR activity is elevated in EpoNi/22.1 cells relative to 293T cells. Supporting this hypothesis, we found that EpoNi/22.1 cells produce significantly more ADAR1 mRNA than 293T cells. Our data suggest that epomophorine bats express ADAR1 at a higher level than non-epomophorine bat species, which exhibit ADAR1 expression similar to or slightly lower than equivalent human cell lines. However, we found a great deal of variation in ADAR1 expression among bat cell lines derived from a diverse group of bats, compared with relatively limited diversity in expression among human cell lines. This would seem to imply that there may be considerable species-specific differences in ADAR1 expression. A potential limitation of the study is that we cannot exclude the possibility that the variation in levels of ADAR1 across the bat cell lines used is related to the immortalized nature of these cells or reflects a specific stage in the development of the respective organisms. Given the IFN-inducible nature of ADAR1 ([@bib62]), it is possible that variable levels of constitutive IFN expression, as has been previously described ([@bib81]), may be responsible. Considering the remarkable diversity of bats ([@bib35]), this would not be unduly surprising. Finally, although it would be preferable to conduct gene silencing experiments to definitively establish the role of ADAR in the hypermutation of GP in EpoNi/22.1 cells, this was not technically feasible due to the lack of a publicly available genome for *Epomops buettikoferi*.

EBOV's MLD and GC are quite flexible and in cell culture appear to be at least partially expendable for GP-pseudotyped vesicular stomatitis virus ([@bib38]). However, whether this applies to genuine virus is not well established. We would thus expect editing of these regions to be well tolerated. However, instead of simply being fitness neutral, we found that some of the observed mutations may have been subject to positive selection in EpoNi/22.1cells, where they closely approached fixation ([Figure 5](#fig5){ref-type="fig"}B). One mutant reconstituted using the reverse genetics system rapidly displaced wild-type virus in competition assays ([Figure 7](#fig7){ref-type="fig"}B). The latter implies that clustering of these mutations on a single genome was not required for increased fitness. Thus, the rapid rise in A-to-G mutations in the EpoNi/22.1-derived populations was likely the result of enzymatic activity and selection.

Evidence of ADAR editing of EBOV genomes has been found in sequences obtained from human cases ([@bib12]; [@bib55]; [@bib76]). Specifically, ADAR-like mutations in GP have been reported, although the activity was less specific than what we have observed ([@bib76]). Our findings raise the possibility that there has been selective pressure to make GP a favorable target for ADAR. The nucleotide compositions of the MLD and GC show a distinct enrichment for "G" nucleotides, and depletion of "A" nucleotides ([Figure S7](#mmc1){ref-type="supplementary-material"}A) ([@bib31]). This increased frequency of "G" contributes to a uniformly high concentration of the 5′-AG-3′ dinucleotide, part of ADAR's preferred 5′(C/A/U)-AG-3′ target motif ([@bib14]; [@bib36]) across the entire GC/MLD region, compared with the other dinucleotides (shown as 3′-GA-5′ in [Figure S7](#mmc1){ref-type="supplementary-material"}B). This specific region is one of the few in the entire genome where 5′-AG-3′ is the most prevalent 5′-AX-3′ dinucleotide. However, the frequency of 5′-GA-3′ (a motif not preferred by ADAR) is also increased in this region. ADAR-driven evolution has been proposed previously for Zika virus and rhabdovirus sigma ([@bib58]). Here, we are reporting evidence for ADAR-driven evolution of portions of the envelope GP that are heavily targeted by the humoral immune response. Taking these facts into consideration, increased susceptibility of this region to ADAR editing may be a strategy to provide an intrinsic means of rapidly generating antibody escape mutants.

In addition to investigating the direct effects of host factors on viral evolution, we also describe changes in population structure that occurred as the result of the virus responding to the replicative environments imposed by the cell lines used. Broadly speaking, purifying selection of EBOV genomes appeared to be a predominant factor in EpoNi/22.1 cells. This is demonstrated by our observation of an increased rate of specific mutations and moderately higher average Shannon entropy in EpoNi/22.1 cells ([Figure 2](#fig2){ref-type="fig"}; [Figure S3](#mmc1){ref-type="supplementary-material"}). Thus diversity was higher, but we identified fewer mutations that exhibited positive fitness compared with 293T cells ([Figure 5](#fig5){ref-type="fig"}; [Figure S2](#mmc1){ref-type="supplementary-material"}). Moving beyond this global view, interpretation of our data must be conservative. Given the disparities in complexity, *in vitro* evolution cannot always be directly compared with *in vivo* evolution. However, patterns of mutations can be reasonably examined for the purposes of understanding aspects of the more general nature of viral evolution and adaptation in a given species. Therefore, our goal was to identify regions of the genome that appeared to be responding to the selective pressures imposed by each cell line. In doing this, our focus was on clusters of mutations rather than individual point mutations. This approach has been used previously in tandem with CirSeq in the context of poliovirus ([@bib2]).

We identified a number of variant clusters associated with passaging in each cell line. In the ORFs, we identified one cluster in NP proximal to the VP30 binding domain, one in VP30 proximal to the NP binding domain, and one within the capping region of the L gene ([Figures S2](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}). An additional set of mutations was identified in the gene-end signal of VP40. A single representative mutant was selected from each identified cluster. The nature of the NP and VP30 mutants is particularly notable. NP N566S falls within a region reported to be important for interaction with host PP2 ([@bib41]), which is recruited to viral intracytoplasmic inclusion bodies by NP ([@bib41]). PP2 participates in the regulation of EBOV transcription via dephosphorylation of VP30, a requirement for transcription initiation ([@bib44]; [@bib48]). VP30 E205G, meanwhile, is proximal to the NP interaction domain of VP30 ([@bib33]) and would likely disrupt an α-helix, significantly disturbing the conformation of the binding domain. Given that NP/VP30 interaction is required for the dynamic phosphorylation of VP30 ([@bib41]; [@bib79]), both of these mutants are predicted to affect EBOV transcription. A double mutant incorporating both VP30 E205G and its equivalent in NP (NP N566S) was nonviable and failed to rescue, implying that the mutants are not complementary but may instead represent an example of convergent evolution. The relative lack of information regarding the structure and function of EBOV L polymerase makes discussion of the potential effects of the capping domain mutant L C1211R difficult, though the mutant and its associated variant cluster may affect the efficiency of mRNA production or on mRNA stability. In contrast, the likely implications of the VP40 gene-end signal mutations are more predictable. Disruption of this highly conserved sequence is almost certain to lead to the production of bicistronic mRNAs, as has been previously described ([@bib5], [@bib6]; [@bib49]). The second ORF in a bicistronic EBOV mRNA is translated at a drastically reduced frequency, therefore reducing the production of the resulting protein ([@bib6]). Our findings with a representative mutant in the EBOV MG system are consistent with this. In EpoNi/22.1 cells, two clusters were identified, the putative ADAR cluster in GP, and another in the methyltransferase domain of L polymerase that likely has similar effects to the L cluster in 293T ([Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}).

In competition and complementation assays performed with rescued mutant viruses, we found that most had a fitness advantage over wild-type virus in both cell lines, suggesting that they were genuinely under positive selection during our passage series ([Figure 7](#fig7){ref-type="fig"}B). However, there were notable cell line-dependent differences in fitness for specific mutants. These phenotypes are likely the result of differences in the cellular microenvironments of the cell lines and may be worthy of future exploration. The performance of L C1211R was somewhat unexpected. Although selection appeared to be consistently beneficial in all three 293T passage series, it had a very marginal fitness advantage in 293T, the cell line in which it was identified, and was less fit than wild-type in EpoNi/22.1. The displacement of NP N566S by VP30 E205G during complementation assays in both cell lines was also unexpected because the fitness of both viruses relative to wild-type in kinetics assays appeared to be similar. It is likely that the difference is relatively small and that as a result was observable only when the viruses were in direct competition. This hypothesis is bolstered by the low absolute frequency of the mutants in the sequencing data. Our failure to rescue the NP N566S/VP30 E205G double mutant suggests that these mutations are mutually exclusive and that cellular co-infection would not be productive. With complementation therefore impossible, if one virus had even a narrow competitive advantage over the other, it would eventually become the dominant genome.

Taken as a whole, our results validate CirSeq as a predictive tool for the identification of variants and variant clusters associated with increased fitness and adaptive evolution. Moreover, we were able to detect these mutants within a relatively short passage series. In both cell lines, variant clusters in the polymerase are associated with potentially adaptive evolution, but 293T cells produced more adaptive variant clusters. These findings are consistent with studies from the 2014--2016 West African epidemic, which revealed that prolonged passaging in humans induced mutations in the NP, VP30, GP, and L genes ([@bib10]; [@bib71]). We attempted to co-localize select mutations identified in the 2014 West African outbreak ([@bib19]) with mutations exhibiting positive fitness in our passaging experiments ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). The GP1 clamp/base shows an interesting (though non-overlapping) cluster of mutations (in three-dimensional \[3D\] space) from both the 2014 epidemic and our passaging experiments.

We have identified several key differences in the evolution of EBOV in a human cell line relative to a cell line derived from a close relative of a potential reservoir host. By comparison with the dramatic differences in replicative and fitness environments faced by arboviruses in their host/vector life cycles, the cell lines used in this study are not extraordinarily divergent as both are of mammalian origin. In this light, our identification of a number of meaningful differences in the short-term evolution of the virus in these cell lines is remarkable. We have presented evidence suggesting that RNA editing enzymes play a greater role in the replication and evolution of EBOV in bat cells. As a result of our findings, we propose that ADAR, a host RNA editing enzyme, may have a role in the evolution of the virus in at least one of the cell lines used. Furthermore, we identified regions within the viral genome associated with potentially adaptive evolution resulting from passaging in these cell lines and characterized selected mutations from these regions. Curiously, many of the mutants identified in variant clusters associated with passaging in these cell lines displayed similar, but not identical, fitness in each cell line, suggesting that relatively minor differences in selective pressures could be responsible for the evolutionary divergence we observed. Overall, our findings would suggest that evolution of EBOV in EpoNi/22.1 cells, and potentially by extension in bats, is driven to a significant degree by host factors acting on the genome. By contrast, EBOV evolution in 293T cells appears to be adaptive, with emphasis on regulation of transcription and transcript stability, as evidenced by variant clusters found within regions of the genome associated with these functions. This pattern fits expectations for a virus that uses bats as a natural reservoir, as evolution in the reservoir host would be drift-driven, while evolution in an incidental host would be more likely to favor positive selection for adaptation ([@bib27]; [@bib71]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit anti-EBOV GP pAbIBT Bioservices0301-015Goat Anti-Rabbit IgG-HRPSouthernBiotechCat\# 4030-05; RRID:[AB_2687483](nif-antibody:AB_2687483){#interref170}**Bacterial and Virus Strains**Ebola virus, variant MayingaRecombinant from full-length cloneNCBI:txid128952**Deposited Data**Consensus FASTQ filesThis paperSRA: PRJNA597079**Experimental Models: Cell Lines**Vero E6ATCCC1008293TATCCCRL-3216EpoNi/22.1Dr. Christian DrostenCVCL_RX73Huh-7Lab stockCVCL_0336**Oligonucleotides**PrimersIDTSee [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.**Recombinant DNA**Ebola virus full length cloneDr. Stuart NicholpEBO**Software and Algorithms**R version 3.4.4[@bib59]<https://www.r-project.org/>Rstudio 1.1.453[@bib60]<http://www.rstudio.com/>Python 2.7.15[@bib72][python.org](http://python.org){#intref0020}CirSeq software (with minor updates)[@bib2]<https://andino.ucsf.edu/CirSeq> (file with minor update available at [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0030})Maximum likelihood Estimation of mutation rates (MaximumLikelihoodEstimation_Q20_Zach.R)This paper Mendeley Data<https://github.com/ashleyacevedo/mutation_rates> and Mendeley Data: [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0040}FitnessEstimator[@bib11] (bioRXiv)<http://biorxiv.org/lookup/doi/10.1101/2020.02.05.936195> (bioRXiv)MultiMatch[@bib11] (bioRXiv)<http://biorxiv.org/lookup/doi/10.1101/2020.02.05.936195> (bioRXiv)ggplot2[@bib78]<https://ggplot2.tidyverse.org/>pLogo[@bib53]<https://plogo.uconn.edu/>pySam[@bib40]<https://github.com/pysam-developers/pysam>ggseqlogo[@bib74]<https://github.com/omarwagih/ggseqlogo>PymolThe PyMOL Molecular Graphics System, Version 1.8.4.0 [@bib63]<https://pymol.org/2/>FoldX[@bib64]<http://foldxsuite.crg.eu/>MODELER[@bib61]<https://salilab.org/modeller/>plot_mutation_rates.RThis Paper, Mendeley DataMendeley Data: [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0090}adar_motif_analysis.RThis Paper, Mendeley DataMendeley Data: [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0095}mismatchesPerRead_combo_AtoGorTtoC_usingPySam.pyThis Paper, Mendeley DataMendeley Data: [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0100}visualizeSameReadDistributions_functions_v3_toPowerPoint.RThis Paper, Mendeley DataMendeley Data: [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0105}shannonEntropy_avgByPassage_toPowerPoint.RThis Paper, Mendeley DataMendeley Data: [https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0110}PolySNP[@bib23][https://doi.org/10.1016/j.jviromet.2007.05.029](10.1016/j.jviromet.2007.05.029){#intref0115}

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to Alexander Bukreyev (<abukreye@utmb.edu>).

### Materials availability {#sec4.2.2}

All unique reagents generated in this study are available from the Lead Contact with appropriate regulatory clearances and a competed Materials Transfer Agreement.

### Data and software availability {#sec4.2.3}

The CirSeq consensus fastq files generated during this study are available at the SRA database under accession number PRJNA597079.

Data containing the EBOV genome used for mapping reads ('*Ebola_fixed.fasta*'), variant counts ('*Q20threshold.txt*''), variant frequencies ('*Q20Freqs_SD.txt*'), mutation rates ('*MutationRates_Q20MLE.txt*'), and variant counts/frequencies paired with codon/amino acid information ('*Q20thresholdTranslated.txt*'') for each replicate-passage combination in the paper are available in Mendeley Data ([https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0125}).

File descriptions are as follows.

Ebola_fixed.fasta: FASTA file of EBOV genome used in the analysis.

Q20threshold.txt: One of the direct outputs of the CirSeq software showing variant counts at each genome position. Column 1 is genome position, column 2 is the reference base, columns 3,4,5, and 6 are the counts for A,C,G, and T/U respectively at that position. In some cases, deposited files are the combined Q20threshold.txt files from multiple sequencing runs.

Q20Freqs_SD.txt: Produced directly from Q20threshold.txt and contains four lines for every position in the genome, each representing a possible variant at that position (including the reference base itself). Column 1 is the genomic position, column 2 is the reference base at the position, column 3 is the potential variant base, column 4 is the counts of the indicated variant base, column 5 is the total counts at the indicated position, column 6 is the frequency of the indicated variant base, and column 7 is an estimate of the standard deviation associated with the given variant.

MutationRates_Q20MLE.txt: Output of 'MaximumLikelihoodEstimation_Q20_Zach.R'. Column 1 is the mutation type, column 2 is the maximum likelihood estimate of the mutation rate, and column 3 is the estimate of standard error.

Q20thresholdTranslated.txt: Provides variant frequency information, but in the context of the protein/codon. Column 1 is the genomic position, column 2 is the amino acid position (NA if non-coding), column 3 is the position within the codon (1,2, or 3), column 4 is the reference codon (single base if non-coding), column 5 is the reference amino acid (NA if non-coding), column 6 is the variant codon (single base if non-coding), column 7 is the variant amino acid (NA if non-coding), column 8 is the counts of the indicated variant, column 9 is the total counts/coverage at the genomic position, column 10 is the frequency of the given variant, column 11 indicates whether the current position is synonymous, nonsynonymous, or noncoding, column 12 indicates the affected protein (or if intergenic).

Code is provided which contributed to [Figures 1](#fig1){ref-type="fig"}A, [3](#fig3){ref-type="fig"}C, [4](#fig4){ref-type="fig"}A, 4B, and [S3](#mmc1){ref-type="supplementary-material"} in Mendeley Data ([https://doi.org/10.17632/42z69y3v35](10.17632/42z69y3v35){#intref0130}).

293T_A\_B_C\_p1-7.rds/EpoNi_A\_B_C\_p1-7.rds: Processed fitness information as taken from the output of the FitnessEstimator based on all 7 viral passages for each replicate. These files provide fitness estimates for each possible variant in the genome, upper and lower boundaries of the estimate, and the number of passages in which adequate coverage was detected. Information is provided for all three replicates in each passage series.

Code descriptions are as follows.

preprocessing_3.py: Contains a minor fix to the preprocessing_3.py script included with the CirSeq package.

MaximumLikelihoodEstimation_Q20_Zach.R: Reads in a 'Q20threshold.txt' and produces a maximum likelihood estimate of the overall mutation rate for each possible variant (AtoC, GtoA, etc...).

plot_mutation_rates.R: Plots the organized output of 'MaximumLikelihoodEstimation_Q20_Zach.R' into boxplots separated by host cell line.

adar_motif_analysis.R: Uses 'Q20Freqs_SD.txt' files as input to generate mutations in the specified quantile and plots them using ggseqlogo. This also generates the output for input to pLogo.

mismatchesPerRead_combo_AtoGorTtoC_usingPySam.py: Uses the mapped output (after sorting and converting to bam format) of the CirSeq pipeline to identify TotC or AtoG which occur on the same read. Note the direct output of this script is with respect to the EBOV coding/+ strand.

visualizeSameReadDistributions_functions_v3_toPowerPoint.R: Visualize the output of 'mismatchesPerRead_combo_AtoGorTtoC_usingPySam.py' to visualize. Note the direct output of this script is with respect to the EBOV coding/+ strand. Graphs were altered for the manuscript to be in reference to the EBOV genomic/- strand.

shannonEntropy_avgByPassage_toPowerPoint.R: Uses 'Q20Freqs_SD.txt' files as input to calculate the average Shannon's entropy across the genome per replicate-passage combination.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell lines {#sec4.3.1}

EpoNi/22.1 bat cells were provided by Dr. Christian Drosten as a gift. This cell line has been described previously ([@bib26]). Cells were maintained in DMEM with F12 and GlutaMAX supplements, plus 10% fetal bovine serum (FBS) and 0.1% gentamicin. 293T cells were maintained in DMEM supplemented with 10% FBS and 0.1% gentamicin. Vero E6 cells were maintained in MEM supplemented with 10%5 FBS and 0.1% gentamicin.

### Viruses {#sec4.3.2}

All viruses used in this study were recombinants based upon a full length clone plasmid provided as a gift by Drs. John Towner and Stuart Nichol (CDC). All work with infectious viruses was performed under BSL-4 conditions by trained personnel in the facilities of Galveston National Laboratory.

Method Details {#sec4.4}
--------------

### Preparation recombinant wild-type virus stocks for passaging {#sec4.4.1}

Rescue of EBOV for the initial passaging experiment was performed as described in [@bib42], using a modified version of the EBOV full length clone provided as a gift by Drs. John Towner and Stuart Nichol (CDC). To generate this clone, the eGFP transgene was excised via restriction digest with BSiWI (New England Biolabs/NEB), following the manufacturer's protocol. The plasmid was re-ligated using T4 DNA ligase (NEB), again following the manufacturer's protocol. The EBOV NP, VP35, L, VP30, and T7 polymerase support plasmids were provided by Dr. Yoshihiro Kawaoka (University of Wisconsin). Following initial rescue, The input virus stock (passage 2) was blind passaged blindly three times ("adaptation passages") in either 293T or EpoNi/22.1 cells, followed by two sequential rounds of terminal dilution in the respective cell lines, from which three clonal virus populations were selected. Isolated viruses were amplified by two blind passages in their respective cell lines to generate viruses with sufficient titers for experimental passages.

### Titration {#sec4.4.2}

Titration was performed by inoculating confluent monolayers of Vero E6 cells with serially diluted virus allowing the virus to adsorb for 1 hour at 37°C, 5% CO2. Following adsorption, a 0.5% methylcellulose, 2% FBS MEM overlay with 0.1% gentamicin was added and the cells were incubated for 5 days at 37°C, 5% CO~2~. Plaques were visualized by plaque immunostaining using an anti-GP polyclonal primary antibody (IBT Bioservices).

### Experimental passages {#sec4.4.3}

For experimental passages, confluent monolayers of 293T or EpoNi/22.1 were inoculated at MOI 0.1 PFU/cell, except for the first passage in 293T, which was performed at MOI 0.01 PFU per cell due to low titers following the amplification passages. Cells were incubated at 37°C/5% CO~2~ for 5 days, after which the supernatants were collected, clarified by centrifugation at 2,000 g, and frozen at −80°C prior to titration and purification. This process was repeated for an additional six experimental passages, at MOI 0.1 PFU/cell.

### Virus purification {#sec4.4.4}

Viruses were purified for RNA extraction by sucrose gradient ultracentrifugation. Supernatants were layered over 25% sucrose (w/v, diluted in 1X STE buffer), and centrifuged at 175,000x*g* for 2 hours at 4°C. Pelleted virus was resuspended in 0.5 mL of STE buffer and sonicated in a water bath (amplitude 95 Hz) for 30 s. Sonicated samples were layered over a 20%--60% sucrose gradient, topped with 1X STE buffer, and centrifuged at 207,000x*g* for 90 minutes at 4°C. The virus band at the sucrose cushion was collected with a pipette, diluted with 1X STE, and then centrifuged at 207,000x*g* for 1 hour at 4°C. Purified virus pellets were resuspended in 100 μL of 1X STE buffer prior to inactivation in 1 mL of Trizol reagent for removal from the BSL-4 and subsequent RNA extraction following the manufacturer's recommended protocol. For 293T cells, host cell rRNA contamination necessitated removal using the GeneRead rRNA Depletion Kit (QIAGEN).

### Sequencing and processing {#sec4.4.5}

Libraries for Circular Sequencing (CirSeq) were generated as described previously ([@bib1]). 300 cycle, single end reads were generated on an Illumina HiSeq 2500 or HiSeq 4000. Resulting fastq files were analyzed as in [@bib2]. A small number of additional counts was recovered using the MultiMatch algorithm ([@bib11]). Variant count files from multiple rounds of sequencing and CirSeq processing were combined to obtain final datasets for analysis. Average coverage per base ranged from 94,461 to 509,722 across all EpoNi/22.1 sequenced libraries. For the 293T libraries, values ranged from 80,797 to 296,930. As a technical note, we did observe some differences in mutation frequency of certain nucleotide substitutions depending on the sequencer used (Illumina HiSeq 2500 versus 4000). The HiSeq 2500 tended to exhibit lower rates of mutation for UG, AC, and CG ([Figure S3](#mmc1){ref-type="supplementary-material"}). However, the differences were not particularly remarkable, and would not be expected to have any meaningful impact on our findings.

### Determination of population mutation frequency {#sec4.4.6}

A maximum likelihood estimation was used to determine individual mutation frequencies for each nucleotide variant type (A to C, G to A, etc.). Only genomic positions with coverage greater than 100,000 were factored in to the calculation. Mann-Whitney U (stats::wilcox.test() in R) tests were used to assess significance between mutation frequencies of a given variant type. Significance testing for each variant type was performed between the 21 data points (7 passages x 3 replicates) from EpoNi/22.1- and 293T-derived viral populations. Note that 293T B passage 7 was excluded from this analysis due to concerns of potential contamination from another passage.

### Identification of 'ADAR' motif {#sec4.4.7}

The highest frequency A to G (genomic strand)/T to C (coding strand) mutations centered around GP's mucin-like domain and glycan cap were identified for each replicate (the specific region analyzed was from coding strand nucleotide 6,723 to 7,540 of the EBOV clone used). Positions containing variant frequencies at or above the indicated quantile in all three replicates were used for motif analysis. For example, a given mutation needed to be at or above the 0.8 quantile in passage 7 of EpoNi A, B, and C to be included. Each sequence consisted of the position of interest and its surrounding 10 nucleotides (5 upstream and 5 downstream; 11 nucleotides total). Sequence logos were created using ggSeqLogo. Variants were only considered if their coverage was greater than 3 × 1/(variant frequency).

### Average number of mutations per read {#sec4.4.8}

The Python package 'pySam' was used to parse a single representative SAM (sorted and converted to BAM) file for each passage output by the CirSeq pipeline. These SAM files represent the mapped consensus read sequences resulting from comparing the head-to-tail repeats generated during the CirSeq workflow. The number of T to C (or A to G) mutations per consensus read was determined, and the average number of each type of mutation per read was determined over the course of passaging for each replicate (including or excluding reads with no mutations). Only reads 80 nt or longer and base calls with a quality score \> = 20 were used. Note that 293T B passage 7 was excluded from this analysis due to concerns of potential contamination from another passage.

### Fitness estimation of variants {#sec4.4.9}

Fitness values were calculated using a version of FitnessEstimator ([@bib11]), using a window size of 6 passages and a bottleneck of 10^6^. Significant fitness variants for a given cell line were variants exhibiting beneficial fitness (wrel.ciLower \[minimum fitness value in 95% confidence interval\] \> 1) or deleterious (wrel.ciUpper \[maximum fitness value in 95% confidence interval\] \< 1) in at least two of three clones. Additionally, it was generally required that at least 5 of the 7 passages had high enough coverage at the position of interest to support the calculated frequency (binomial value in FitnessEstimator). The average of these fitness values were used to compare variant fitness between cell lines.

### Visualization of PDB files and determination of ΔΔG value {#sec4.4.10}

PDB files were visualized using PyMol. A previously published structure of VP30 (5T3T) was used for visualization and stability testing. A structural prediction of the EBOV L protein was constructed using MODELER, using VSV L (5a22) as a template. ΔΔG values were estimated using FoldX. Each PDB file was first repaired (FoldX command = RepairPDB), then a model was built containing the mutation of interest (command = BuildModel). [Figure S6](#mmc1){ref-type="supplementary-material"} uses structures of GP (PDB structure 3csy) and NP (model from [@bib30]).

### Calculation of average Shannon's entropy {#sec4.4.11}

Entropy was calculated for each nucleotide position in the EBOV genome (at each passage for each replicate). Shannon's entropy for an individual nucleotide was calculated as

Entropy~single\ nucleotide~ = -Σ(f ^∗^ log~4~(f)) where 'f' is the frequency (i.e., probability) of each possible nucleotide at that position. The average of this value across the genome was calculated for each replicate at each passage, then plotted. C to U (genomic strand) variants were excluded from the calculations. Effect size (Cohen's d) in the region of the glycan cap and mucin-like domain (defined as nucleotide positions 6723 to 7540), was determined using the cohen.d function from the 'effsize' R package. Distribution of Shannon entropy per base in all 293T clones was compared to the distribution of Shannon entropies per base for all EpoNi/22.1 clones at each passage. Only positions with coverage greater than 100,000 were evaluated in any calculation of Shannon entropy. This resulted in the comparison of 1,861 positions for EpoNi-derived virus to 2,152 positions for 293T-derived populations across all replicates at passage 6.

### Preparation of mutant viruses {#sec4.4.12}

Mutant viruses were prepared using either site-directed mutagenesis (NP N566S, VP30 E205G, L C1211R, L S1994G), or by ligating in a synthetic DNA construct (GP L256P). Site-directed mutagenesis was performed using the Q5 Site-directed mutagenesis kit from NEB. Primers were designed using NEB's online tool. As the annealing temperatures suggested by this tool were not successful, an annealing temperature gradient was performed to generate mutant plasmids. Other than this deviation, the manufacturer's protocol was adhered to. For the GP mutant, double-stranded DNA fragments (gBlocks, Integrated DNA Technologies) were first subcloned into the SalI and BbsI sites of a pUC19 construct containing the portion of the EBOV FLC between SalI and SacI. The SalI/SacI fragment of this new construct was digested out and inserted via restriction cloning between the SalI and SacI sites of the FLC plasmid. Viruses were rescued following a modified version of the protocol described by [@bib70]. Briefly, 90% confluent 6-well plates of Huh-7 cells in standard maintenance media were transfected with 1 μg pCEZ-NP, 0.5 μg pCEZ-VP35, 0.3 μg pCEZ-VP30, 2 μg pCEZ-L-co, 1 μg PLASMID-T7, and 1 μg of the appropriate FLC plasmid. Transfection complexes were prepared using transIT-LT1 (Mirus), with a ratio of 2 μL of transfection reagent per microgram of plasmid DNA. The next day, media was replaced with fresh DMEM high glucose with 2% FBS and 0.1% gentamicin. Five days post-transfection, supernatants were pooled and adsorbed onto T75 flasks of Huh-7 overnight, with fresh media added the next day. Five days post infection, viruses were collected. To produce stocks of sufficient titer for experiments, viruses were passaged one time on Vero E6 cells infected at MOI 0.1 PFU/cell. Stocks were titrated by immunostaining in 96 well plates.

### Preparation of minigenomes {#sec4.4.13}

The bicistronic MG was prepared in the Bukreyev lab from a monocistronic MG provided by Dr. Elke Mühlberger (Boston University) ([@bib50]). This MG consists of the 3′ genomic leader, plus the NP 5′ UTR controlling transcription of a firefly luciferase ORF, followed by the VP40-GP gene junction region, including the GP 5′ UTR, which controls transcription of a Renilla luciferase ORF. The Renilla luciferase ORF is followed by the L gene 3′ UTR and the 5′ genomic trailer. Rescue and MG support plasmids (excepting the codon-optimized L plasmid) were as described above. The codon optimized L polymerase plasmid was synthesized by Genescript.

### Quantitative analysis of ADAR1 RNA {#sec4.4.14}

Actively expanding cell monolayers were lysed in Trizol following manufacturer's protocol. Following RNA extraction, cDNAs were prepared using the iScript cDNA synthesis kit (BioRad) using 20 ng of total RNA. 1 ng of cDNA was used in subsequent qPCR reactions, performed with the iTaq universal SYBR Green Master Mix kit (BioRad). Primers and standards for absolute quantitation were obtained from Integrated DNA Technologies (IDT). Bat ADAR1 and 18 s rRNA primers were designed using the Pteropus vampyrus genome due to the lack of published Epomops genomes for certain species used. Primers and standards used and shown in [Table S1](#mmc1){ref-type="supplementary-material"}. Primers had no more than one centrally placed mismatch relative to their expected targets, where known. qPCR was performed on a QuantStudio 6 thermal cycler. ADAR1 copy number was normalized to 18 s rRNA copy number. Significance was tested using a 1-way ANOVA with a Tukey's post hoc test for multiple comparisons.

### Multistep replication kinetics {#sec4.4.15}

Assays were performed for all mutants on both EpoNi/22.1 and 293T. Samples were collected at 24, 48, 72, and 96 hours post infection. For each time point, three wells of a 24 well plate were infected at MOI 0.01 PFU/cell, and the virus was allowed to adsorb for 30 minutes, after which wells were washed twice with PBS before fresh media was added. Time course samples were titrated by immunostaining in 96 well plates. Significance was tested using one-way ANOVA, with a Dunnett's post hoc correction.

### Competition and complementation assays {#sec4.4.16}

Assays were performed by mixing selected mutant viruses 1:1 by immunostain titer. For competition assays, 293T or EpoNi/22.1 cells in 12 well plates were infected for passage 1 at MOI 0.1 PFU/cell in triplicate, otherwise following the infection protocol as described for kinetics assays. Passage 1 infections for complementation assays were performed at MOI 3 PFU/cell. When significant CPE was observed (3 dpi for complementation assays, 4 dpi for competition assays), supernatants were collected. For all subsequent passages, cells for competition assays were infected with a 1:100 dilution of the supernatant from the previous passage. For complementation assays, EpoNi/22.1 cells were infected with ¼ of the supernatant from the previous passage, while 293T cells were infected with ½ of the supernatant from the previous passage, to account for the larger number of 293T cells per well and ensure an MOI greater than 1 PFU/cell. Samples of inocula (in triplicate), and supernatants were removed from BSL-4 in Trizol (Thermo-Fisher) for column-based RNA extraction (Zymo Direct-Zol RNA micro-prep). [Figure 7](#fig7){ref-type="fig"}A presents the experimental design in schematic form. RT-PCR amplicons were generated (QIAGEN One Step RT-PCR kit) using the primers provided in [Table S2](#mmc1){ref-type="supplementary-material"}, and were Sanger sequenced with technical duplicates following enzymatic PCR cleanup (Genewiz). Analysis of sequence data was performed via poly-SNP ([@bib23]), using the area under the curve method to determine the relative proportion of each virus within the sequenced population. Significance was tested with 2-way ANOVA, with a Bonferroni post hoc correction.

### Minigenome assays {#sec4.4.17}

MG transfections were performed in triplicate in 6 well plates as previously described ([@bib29]). A codon-optimized L polymerase plasmid was used. Control transfections omitting the L polymerase plasmid were performed with both the wild-type and mutant bicistronic MGs. Dual-luciferase assays were performed to assess the efficiency of translation of the Renilla luciferase ORF relative to the firefly luciferase open reading frame by taking the FFL:RL signal ratio. Comparison of the efficiency of translation from the wild-type MG to translation from the mutant MG was determined by dividing the mutant ratio by the wild-type ratio and taking the reciprocal. This yields a value representative of the loss of efficiency resulting from the mutation. Data presented are representative of three independent experiments. Significance was tested using one-way ANOVA, with a Dunnett's post hoc correction.

Quantification and Statistical Assays {#sec4.5}
-------------------------------------

Additional details for specific assays and tests can be found in the relevant Method Details sections and figure legends.

Statistical differences in mutation rate ([Figure 1](#fig1){ref-type="fig"}) were determined using the Mann-Whitney U (stats::wilcox.test() in R) followed by multiple comparison testing using the Bonferroni method ('*p.adjust(method = "bonferroni")'* in R). Significance testing for each variant type was performed between the 21 data points (7 passages x 3 replicates) from EpoNi/22.1- and 293T-derived viral populations. Note that 293T B passage 7 was excluded from this analysis due to concerns of potential contamination from another passage.

Effect size of the difference in Shannon's entropy between EpoNi- and 293T-derived viral populations was determined using the effsize::cohen.d() function in R. Effect size was only compared for the individual nucleotides from position 6723 to 7540 (with respect to the reference genome used in this manuscript).

Data for virology assays were compiled and analyzed in Prism.
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